Shandong Anhong Pharmaceutical Co., Ltd.October 30, 2020

FDA 483 - Shandong Anhong Pharmaceutical Co., Ltd. - October 30, 2020

View on Dashboard

Discuss this record with AI

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Shandong Anhong Pharmaceutical Co., Ltd.

Record Details

Shandong Anhong Pharmaceutical Co., Ltd. was cited for significant deficiencies in its manufacturing processes and quality control systems. Observations include inadequate cleaning and disinfection procedures, failure to follow sterile product contamination prevention protocols, and insufficient laboratory controls for impurity evaluation. These issues indicate a moderate to severe risk to product quality and patient safety.

Company: Shandong Anhong Pharmaceutical Co., Ltd.
Inspection Date: October 30, 2020
Product Type: Drugs
Office: Office of Biological Products Operations - Division I
Person: Jonathan W. Chapman (investigator)

Open in Dashboard

ID · 9f201cbb-010b-412d-b8a8-04838f3940ff